Deucravacitinib, an oral, selective, allosteric, tyrosine kinase 2 inhibitor, in patients with active SLE: efficacy on patient-reported outcomes in a phase II randomised trialMarta Mosca, Vibeke Strand, Laurent Arnaud et al.|Lupus Science & Medicine|2025Cited by 5
POS0781 EFFICACY AND SAFETY OF ORAL DEUCRAVACITINIB IN PATIENTS WITH CUTANEOUS MANIFESTATIONS OF LUPUS ERYTHEMATOSUS: RESULTS FROM PAISLEY CLE, A GLOBAL, RANDOMIZED, PLACEBO-CONTROLLED, PHASE 2 TRIALJ.F. Merola, V.P. Werth, Anna Luisa Kühn et al.|Annals of the Rheumatic Diseases|2025Cited by 5
IMPACT OF COMORBIDITIES ON TIME IN THERAPEUTIC RANGE IN PATIENTS WITH NONVALVULAR ATRIAL FIBRILLATIONJiyoon Choi, Winnie W. Nelson, C.V. Damaraju et al.|Journal of the American College of Cardiology|2012Cited by 4